Gilead Sciences (GILD) Enterprise Value Growth (1y) (2010 - 2026)

Gilead Sciences (GILD) Enterprise Value Growth (1y) (2010 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.53%
Dec 31, 2025 23.41%
Sep 30, 2025 -45.15%
Jun 30, 2025 -85.47%
Mar 31, 2025 -66.81%
Dec 31, 2024 -37.11%
Sep 30, 2024 26.17%
Jun 30, 2024 57.57%
Mar 31, 2024 19.02%
Dec 31, 2023 -14.53%
Sep 30, 2023 -22.03%
Jun 30, 2023 -18.42%
Mar 31, 2023 -11.11%
Dec 31, 2022 1.67%
Sep 30, 2022 0.92%
Jun 30, 2022 12.80%
Mar 31, 2022 5.61%
Dec 31, 2021 11.69%
Sep 30, 2021 76.04%
Jun 30, 2021 65.33%